Name: IKT Balance Sheet - Inhibikase Therapeutics Assets & Debt | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Total Assets, Current Assets, Cash and Equivalents, Total Liabilities, Long-term Debt, Short-term Debt, Shareholders Equity, Working Capital, Book Value Per Share

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

IKT - Inhibikase Therapeutics, Inc.

USD | NASDAQ | Healthcare

IKT Balance Sheet - Inhibikase Therapeutics Assets & Debt | Ledgeburg

(in millions of USD)	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Cash And Short Term Investments
Cash And Equivalents	178.8	97.5	9.2	7.2	40.8	-	-
Restricted Cash	-	-	-	-	-	-	-
Short Term Investments	39.5	41.1	4.1	15.9	0.0	-	-
Cash And Short Term Investments	218.3	138.6	13.3	23.1	40.8	-	-
Receivables
Accounts Receivable	-	-	-	-	-	-	-
Current Assets
Inventory	-	-	-	-	-	-	-
Prepaid Expenses	0.3	0.8	0.7	0.2	1.5	0.1	-
Non-Current Assets
Property, Plant & Equipment Gross	0.0	0.1	0.1	0.2	-	-	-
Accumulated Depreciation	-	-	-	-	-	-
Current Liabilities
Accounts Payable	1.2	0.9	0.6	1.2	1.1	1.7	-
Short Term Debt	-	-	-	-	-	-	-
Non-Current Liabilities
Long Term Debt	-	-	0.4	-	0.2	-	-
Operating Lease Liabilities Non-Current	-	-	0.1	0.2	-	-
Common Equity
Common Stock	0.1	0.1	0.0	0.0	0.0	0.0	-
Additional Paid In Capital	-	-	-	-	-	-
Supplementary Data
Total Debt	-	-	0.4	-	0.2	-	-
Net debt	-	-	(12.9)	-	(40.5)	-	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19
Cash And Short Term Investments
Cash And Equivalents	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Current Liabilities
Accounts Payable	1.6	1.2	0.6	2.7	1.7	0.9	2.5	1.3	1.3	0.6	0.7	0.8	1.0	1.2	0.8	0.9	0.8	1.1	0.6	0.9	0.7	1.7	-	-	-	-
Short Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Lease Liabilities Current	-	-	-	-	-	-	-	0.2	0.2	-	0.1	0.1	0.1	-	0.1	-
Accrued Expenses	4.1	4.1	3.7	3.1	3.5	2.7	2.2	2.0	2.5	2.3	1.9	1.8	1.6	2.4	2.3	3.6	3.6	2.7
Other Current Liabilities	-	-	-	-	-	-	-	-	-	-	2.7	2.7	2.7	-	3.1	-	-
Total Current Liabilities	5.7	8.3	6.7	8.8	8.6	3.7	4.9	3.7	4.2	3.4	2.7	2.7	2.7	3.7	3.2	-

Common Equity
Common Stock	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-	-	-	-
Additional Paid In Capital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	(159.1)	(142.7)	(129.9)	(118.0)	(108.1)	(94.4)	(82.3)	(76.5)	(71.6)	(66.9)	(62.7)	(58.1)	(52.3)	(47.9)	(43.6)	(39.1)	(34.5)
Accumulated Other Comprehensive Income	(0.0)	0.0	(0.0)	(0.0)	(0.0)	(0.0)	0.0	(0.0)	(0.0)	0.0	(0.0)	(0.0)	0.2	0.1	0.0
Treasury Stock	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Stockholders Equity	167.6	172.9	72.9	80.1	85.7	94.9	(0.5)	5.1	6.8	11.0	15.0	19.5	25.3	21.0	25.1	29.5	34.0
Total Equity	167.6	172.9	72.9	80.1	85.7	94.9	(0.5)	5.1	6.8	11.0	15.0	19.5	25.3	21.0	25.1	29.5	34.0	38.4

Supplementary Data
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.2	0.2	1.2	-	-	-	-	-
Net debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Working Capital	166.5	171.8	71.8	80.0	85.6	94.7	(0.7)	4.9	6.6	10.8	14.8	19.3	25.0	20.7	24.8	-	-	38.4
Book Value	167.6	172.9	72.9	80.1	85.7	94.9	(0.5)	5.1	6.8	11.0	15.0	19.5	25.3	21.0	25.1	29.5	34.0	38.4
Tangible Book Value	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-